Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that relentless routine of meetings, deadlines, and whatnot has returned. And it has brought a spot of rain along with it. Nonetheless, we are pushing ahead with our usual reliance on cups of stimulation and, as always, we invite you to join us. Meanwhile, here are some tidbits. Have a smashing day and do stay in touch …
The US pharmaceutical industry trade group plans to send scientists, researchers, and patients to meet with congressional lawmakers in a bid to fend off criticism over drug prices, The Hill reports. The plan represents a big shift from what Steve Ubl, who heads the Pharmaceutical Researchers and Manufacturers of America, acknowledges has been a strategy “focused on defense.”
The Scottish government is being questioned about withholding details of a $30 million fund for treating patients with rare diseases, and it turns out much of it was spent on just one drug, according to The Scotland Herald. Nearly 86 percent of its budget was spent on the Kalydeco cystic fibrosis drug sold by Vertex Pharmaceuticals. The treatment, also known as Ivacaftor, costs about $255,000 per patient.
About the Author Reprints
